1st Apr 2015 16:10
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc ('Company').
On 31 March 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £15.66 per Ordinary Share, and notional ADSs at a price of $46.80 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2015 to 31 March 2015:
Non Executive Director | Ordinary Shares | No. of ADSs |
Sir Christopher Gent | 3,991.060 | |
Professor Sir Roy Anderson | 458.972 | |
Dr Stephanie Burns | 486.201 | |
Stacey Cartwright | 339.240 | |
Lynn Elsenhans | 1,103.464 | |
Sir Philip Hampton | 339.240 | |
Judy Lewent | 539.049 | |
Sir Deryck Maughan | 1,479.741 | |
Dr Daniel Podolsky | 1,109.806 | |
Urs Rohner | 339.240 | |
Tom de Swaan | 419.061 | |
Jing Ulrich | 306.518 | |
Hans Wijers | 339.240 | |
The Company and the Non-Executive Directors were informed of these allocations on 1 April 2015.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
1 April 2015
Related Shares:
Glaxosmithkline